Technology

OBI developed a unique glycan-based ADC platform (GlycOBI^®) , which was designed in a ‘Plug and Play’ format and compatible with different antibodies (mono- or multi-specific), linkers, and payloads in various drug-antibody-ratio (DARs). Utilizing OBI’s proprietary enzymatic technology (EndoSymeOBI^®) and novel linker-payload technology (HYPrOBI^®), site-specific homogenous ADCs are generated, ranging from DAR2 to DAR16, with an efficient and scalable process. The conjugation process of GlycOBI^® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI’s linker technology has improved conjugation efficiency of the payload and reduced aggregation and expanded the half-life of the ADC products. GlycOBI^® conjugation technology has overcome the limitations of traditional ADCs and achieved better efficacy and stability in various in-vivo tests.

GlycOBI DUO™ Technology is an advanced site-specific conjugation platform developed by OBI to enable the next generation of antibody-drug conjugates (ADCs).

Leveraging glycan engineering, the platform enables modular installation of two distinct payloads with different MOAs, in flexible and tunable ratios via single- or multi-site conjugation strategies.

By leveraging the unique architecture of the GlycOBI DUO™ system, this dual-payload approach addresses key limitations of traditional ADCs. The ability to combine complementary MOAs enhances antitumor potency and broadens therapeutic coverage, allowing ADCs to more effectively tackle tumor heterogeneity. Additionally, the strategic pairing of payloads offers a potential strategy to overcome drug resistance mechanisms, providing sustained efficacy even in challenging tumors. GlycOBI DUO™ incorporates GlycOBI^® and HYPrOBI^® technologies to enable the generation of dual-payload ADCs without introducing potential aggregation liabilities.

The ThiOBI^® platform represents a cutting-edge approach for the development of next-generation cysteine (Cys)-based drug conjugates, supporting a wide range of cysteine-containing biomolecules, such as nanobodies, antibody fragments, and peptides. Built upon OBI’s proprietary HYPrOBI^® linker, ThiOBI^® utilizes a novel hydrophilic and stable linker that enhances solubility, prolongs circulation stability, and ensures efficient drug release at the tumor site. Additionally, its irreversible thiol conjugation chemistry enables precise and selective modification of Cys residues, offering meticulous control over the conjugation process and consistent product quality. The technology also supports dual-payload ADC designs without inducing aggregation, offering expanded flexibility for complex therapeutic strategies. ThiOBI^® was presented at AACR 2025, showcasing its conjugation strategy and promising preclinical data.

EndoSymeOBI^® is our proprietary enzyme technology which allows antibody glycan modification within a one-pot reaction. This includes removing multiple types of sugar molecules and linking specially designed sugar molecules, or their derivatives, to the antibody. The technology has a broad application with high glycan remodeling efficiency on various antibodies. EndoSymeOBI^® processed antibodies retain their stability and binding activity without altering disulfide bonds. Furthermore, EndoSymeOBI is produced by a recombinant approach with improved enzyme purity, quality and consistent activity. The EndoSymeOBI^® platform excels in diverse applications from sugar molecule removal to site-specific antibody-drug conjugate (ADC) production, and antibody homogenization. EndoSymeOBI^® directly enhances the functionality of antibodies, offering more effective solutions for developing therapeutics for cancer, immune system diseases and others.

HYPrOBI^® is OBI’s proprietary linker, rationally designed to enhance the overall stability, efficacy, and pharmacological performance of ADCs. This innovative technology integrates two critical features: the “masking” and the “shielding” effects.

The masking effect incorporates hydrophilic moieties into the linker structure to effectively mask the hydrophobicity of the payload. This design reduces the propensity for aggregation, improves solubility, and allows greater flexibility in achieving higher drug antibody ratios (DARs) without compromising ADC stability.

The shielding effect introduces a strategic steric hindrance around the payload, preventing premature drug release in circulation. This ensures that the payload remains stable and only gets released selectively after locating to the target tumor site. The result is a controlled, slow-release profile that supports expanded and durable anti-tumor activity.